Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by atai Life Sciences

< Previous 1 2 Next >
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences to Participate in Upcoming September Investor Conferences
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences to Participate in Upcoming June Investor Conferences
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences to Participate in Upcoming May Investor Conference
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces R&D Day Agenda
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.